Sports News

Revolution Medicines Joins Rank Of Stocks With RS Ratings Over 90

Revolution Medicines (RVMD) had its Relative Strength (RS) Rating upgraded from 87 to 93 Thursday.


IBD’s unique RS Rating identifies technical performance by showing how a stock’s price action over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research shows that the best-performing stocks often have an RS Rating north of 80 at the beginning of a new price run.

How To Use Stock Charts To Stay Profitable And Protected

While Revolution Medicines is not near a proper buy point right now, see if it is able to form and break out of a proper chart pattern.

Revolution Medicines reported 0% EPS growth in its most recent report. Revenue rose -95%. The company is expected to report its latest earnings and sales numbers on or around May 6.

The company holds the No. 205 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences (NBIX), Alpine Immune Sciences (ALPN) and Catalyst Pharmaceuticals (CPRX) are among the top 5 highly rated stocks within the group.


Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Related Articles

Leave a Reply

Back to top button